Renalytix AI plc Asset Resilience Ratio
Renalytix AI plc asset resilience ratio. Renalytix AI plc (RENX) has an Asset Resilience Ratio of 3.64% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RENX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Renalytix AI plc (2012–2025)
Asset resilience ratio of Renalytix AI plc from 2012 to 2025. This chart shows how Renalytix AI plc's Asset Resilience Ratio has changed over time. Read RENX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Renalytix AI plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RENX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX417.00K | 3.64% |
| Total Liquid Assets | GBX417.00K | 3.64% |
Asset Resilience Insights
- Limited Liquidity: Renalytix AI plc maintains only 3.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Renalytix AI plc Industry Peers by Asset Resilience Ratio
Compare Renalytix AI plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Reliq Health Technologies Inc
V:RHT |
Health Information Services | 0.45% |
|
Pro Medicus Ltd
AU:PME |
Health Information Services | 17.07% |
|
Cogstate Ltd
AU:CGS |
Health Information Services | 54.90% |
|
ARTRYA Ltd
AU:AYA |
Health Information Services | 32.70% |
|
Echoiq Ltd
AU:EIQ |
Health Information Services | 11.12% |
|
Alcidion Group Ltd
AU:ALC |
Health Information Services | 32.45% |
|
Oneview Healthcare Plc
AU:ONE |
Health Information Services | 29.71% |
|
Singular Health Group Ltd
AU:SHG |
Health Information Services | 66.96% |
Renalytix AI plc Asset Resilience Ratio by Year (2012–2025)
Renalytix AI plc asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Renalytix AI plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 1.64% | GBX100.00K ≈ $12.17 |
GBX6.10 Million ≈ $742.19 |
-7.14pp |
| 2024-06-30 | 8.78% | GBX700.00K ≈ $85.17 |
GBX7.97 Million ≈ $969.96 |
+7.30pp |
| 2023-12-31 | 1.48% | GBX1.11 Billion ≈ $135.30K |
GBX75.27 Billion ≈ $9.16 Million |
-1.99pp |
| 2023-06-30 | 3.47% | GBX1.46 Million ≈ $177.64 |
GBX42.12 Million ≈ $5.12K |
-0.87pp |
| 2022-06-30 | 4.34% | GBX2.74 Million ≈ $333.87 |
GBX63.26 Million ≈ $7.70K |
-4.72pp |
| 2021-06-30 | 9.06% | GBX9.29 Million ≈ $1.13K |
GBX102.58 Million ≈ $12.48K |
+6.68pp |
| 2020-06-30 | 2.38% | GBX982.00K ≈ $119.48 |
GBX41.30 Million ≈ $5.02K |
-1.06pp |
| 2019-06-30 | 3.44% | GBX994.00K ≈ $120.94 |
GBX28.92 Million ≈ $3.52K |
+2.44pp |
| 2016-12-31 | 1.00% | GBX594.67 Million ≈ $72.35K |
GBX59.39 Billion ≈ $7.23 Million |
-0.14pp |
| 2015-12-31 | 1.14% | GBX647.30 Million ≈ $78.76K |
GBX56.80 Billion ≈ $6.91 Million |
-0.11pp |
| 2014-12-31 | 1.25% | GBX725.05 Million ≈ $88.22K |
GBX58.13 Billion ≈ $7.07 Million |
-0.80pp |
| 2013-12-31 | 2.05% | GBX1.29 Billion ≈ $156.50K |
GBX62.68 Billion ≈ $7.63 Million |
+0.51pp |
| 2012-12-31 | 1.54% | GBX937.44 Million ≈ $114.06K |
GBX60.90 Billion ≈ $7.41 Million |
-- |
About Renalytix AI plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more